Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma.
Wood CG, Ferguson JE 3rd, Parker JS, Moore DT, Whisenant JG, Maygarden SJ, Wallen EM, Kim WY, Milowsky MI, Beckermann KE, Davis NB, Haake SM, Karam JA, Bortone DS, Vincent BG, Powles T, Rathmell WK. Wood CG, et al. Among authors: milowsky mi. JCI Insight. 2020 Nov 19;5(22):e132852. doi: 10.1172/jci.insight.132852. JCI Insight. 2020. PMID: 33208553 Free PMC article. Clinical Trial.
Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression.
Brooks SA, Khandani AH, Fielding JR, Lin W, Sills T, Lee Y, Arreola A, Milowsky MI, Wallen EM, Woods ME, Smith AB, Nielsen ME, Parker JS, Lalush DS, Rathmell WK. Brooks SA, et al. Among authors: milowsky mi. Clin Cancer Res. 2016 Jun 15;22(12):2950-9. doi: 10.1158/1078-0432.CCR-15-2115. Epub 2016 Jan 19. Clin Cancer Res. 2016. PMID: 26787754 Free PMC article.
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.
Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA, Zakharia Y, Milowsky MI, Shah SA, Bellmunt J, Grivas P, Emamekhoo H, Davis NB, Gupta S, Hoimes C, Campbell MT, Alva A, Koshkin VS. Jindal T, et al. Among authors: milowsky mi. Eur Urol Oncol. 2024 Dec 20:S2588-9311(24)00289-X. doi: 10.1016/j.euo.2024.12.006. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39709257 Free article.
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.
Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Agerbaek M, Jha G, Stenner F, Ye D, Giudici F, Dutta S, Askelson M, Nasroulah F, Zhang J, Brophy L, Bajorin DF. Galsky MD, et al. Among authors: milowsky mi. J Clin Oncol. 2025 Jan;43(1):15-21. doi: 10.1200/JCO.24.00340. Epub 2024 Oct 11. J Clin Oncol. 2025. PMID: 39393026 Clinical Trial.
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201).
Jensen JL, Bobek O, Chan ICC, Miller BC, Hillman DW, Heller G, Druley T, Armstrong AJ, Morris MJ, Milowsky MI, Beltran H, Bolton KL, Coombs CC. Jensen JL, et al. Among authors: milowsky mi. Clin Cancer Res. 2024 Nov 1;30(21):4910-4919. doi: 10.1158/1078-0432.CCR-24-0803. Clin Cancer Res. 2024. PMID: 39287426 Clinical Trial.
207 results